Gland Pharma Limited - Asset Resilience Ratio
Gland Pharma Limited (GLAND) has an Asset Resilience Ratio of 0.59% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Gland Pharma Limited to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2026)
This chart shows how Gland Pharma Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Gland Pharma Limited (GLAND) total assets.
Liquid Assets Composition Over Time
This chart breaks down Gland Pharma Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read GLAND total debt and obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs737.41 Million | 0.59% |
| Total Liquid Assets | Rs737.41 Million | 0.59% |
Asset Resilience Insights
- Limited Liquidity: Gland Pharma Limited maintains only 0.59% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Gland Pharma Limited Industry Peers by Asset Resilience Ratio
Compare Gland Pharma Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Harbin Gloria Pharmaceuticals
SHE:002437 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Jiuzhitang Co Ltd
SHE:000989 |
Drug Manufacturers - Specialty & Generic | 7.86% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
Annual Asset Resilience Ratio for Gland Pharma Limited (2018–2026)
The table below shows the annual Asset Resilience Ratio data for Gland Pharma Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-03-31 | 0.59% | Rs737.41 Million ≈ $7.97 Million |
Rs125.11 Billion ≈ $1.35 Billion |
-2.94pp |
| 2025-03-31 | 3.53% | Rs3.96 Billion ≈ $42.83 Million |
Rs112.25 Billion ≈ $1.21 Billion |
-11.31pp |
| 2024-03-31 | 14.84% | Rs15.82 Billion ≈ $171.05 Million |
Rs106.61 Billion ≈ $1.15 Billion |
-6.29pp |
| 2023-03-31 | 21.12% | Rs18.54 Billion ≈ $200.50 Million |
Rs87.78 Billion ≈ $949.26 Million |
-16.24pp |
| 2022-03-31 | 37.36% | Rs29.27 Billion ≈ $316.53 Million |
Rs78.34 Billion ≈ $847.18 Million |
-1.29pp |
| 2021-03-31 | 38.65% | Rs25.11 Billion ≈ $271.52 Million |
Rs64.96 Billion ≈ $702.53 Million |
+10.68pp |
| 2020-03-31 | 27.97% | Rs11.43 Billion ≈ $123.58 Million |
Rs40.86 Billion ≈ $441.89 Million |
+14.22pp |
| 2019-03-31 | 13.75% | Rs4.84 Billion ≈ $52.38 Million |
Rs35.24 Billion ≈ $381.06 Million |
+4.25pp |
| 2018-03-31 | 9.50% | Rs2.78 Billion ≈ $30.10 Million |
Rs29.29 Billion ≈ $316.81 Million |
-- |
About Gland Pharma Limited
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic … Read more